BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 7505979)

  • 1. Using PSA to eliminate the staging radionuclide bone scan. Significant economic implications.
    Oesterling JE
    Urol Clin North Am; 1993 Nov; 20(4):705-11. PubMed ID: 7505979
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The use of prostate-specific antigen in staging patients with newly diagnosed prostate cancer.
    Oesterling JE; Martin SK; Bergstralh EJ; Lowe FC
    JAMA; 1993 Jan; 269(1):57-60. PubMed ID: 7677962
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Serum prostate-specific antigen as a predictor of radiographic staging studies in newly diagnosed prostate cancer.
    Huncharek M; Muscat J
    Cancer Invest; 1995; 13(1):31-5. PubMed ID: 7530590
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Using prostate-specific antigen to eliminate the staging radionuclide bone scan.
    Lee CT; Oesterling JE
    Urol Clin North Am; 1997 May; 24(2):389-94. PubMed ID: 9126236
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Can initial prostate specific antigen determinations eliminate the need for bone scans in patients with newly diagnosed prostate carcinoma? A multicenter retrospective study in Japan.
    Kosuda S; Yoshimura I; Aizawa T; Koizumi K; Akakura K; Kuyama J; Ichihara K; Yonese J; Koizumi M; Nakashima J; Fujii H
    Cancer; 2002 Feb; 94(4):964-72. PubMed ID: 11920464
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Predicting radionuclide bone scan findings in patients with newly diagnosed, untreated prostate cancer: prostate specific antigen is superior to all other clinical parameters.
    Chybowski FM; Keller JJ; Bergstralh EJ; Oesterling JE
    J Urol; 1991 Feb; 145(2):313-8. PubMed ID: 1703240
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Is bone scintigraphy necessary in initial staging of prostate cancer patients?
    Jaukovic L; Adjinovic B; Cerovic S; Joksimovic M; Soldatovic Z
    Hell J Nucl Med; 2011; 14(2):126-30. PubMed ID: 21761013
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Influence of local tumour stage and grade on reliability of serum prostate-specific antigen in predicting skeletal metastases in patients with adenocarcinoma of the prostate.
    Bruwer G; Heyns CF; Allen FJ
    Eur Urol; 1999; 35(3):223-7. PubMed ID: 10072624
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Relationship between pretreatment serum levels of prostate specific antigen and bone metastasis in prostate cancer].
    Kageyama Y; Kihara K; Kamata S; Nagahama K; Yonese J; Fukuda H; Tosaka A; Nagamatsu H; Ishizaka K; Tsujii T; Kitahara S; Morita T; Oshima H
    Hinyokika Kiyo; 1996 Mar; 42(3):197-9. PubMed ID: 8619388
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prostate carcinoma staging. Clinical utility of bone alkaline phosphatase in addition to prostate specific antigen.
    Morote J; Lorente JA; Encabo G
    Cancer; 1996 Dec; 78(11):2374-8. PubMed ID: 8941009
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Do all patients with newly diagnosed prostate cancer need staging radionuclide bone scan? A retrospective study.
    Al-Ghazo MA; Ghalayini IF; Al-Azab RS; Bani-Hani I; Barham A; Haddad Y
    Int Braz J Urol; 2010; 36(6):685-91; discussion 691-2. PubMed ID: 21176275
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [The relationship between the serum level of prostate specific antigen and bone and CT scans in the staging of the primary carcinoma of the prostate].
    Hoefman E; Hulshof MC; de Reijke TM; Bruijnes E; Redekop WK; van Straalen JP
    Ned Tijdschr Geneeskd; 1998 May; 142(20):1142-6. PubMed ID: 9623236
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The clinical value of prostate-specific antigen and bone scintigraphy in the staging of patients with newly diagnosed, pathologically proven prostate cancer.
    Rudoni M; Antonini G; Favro M; Baroli A; Brambilla M; Cardani G; Ciardi L; Sacchetti GM; Inglese E
    Eur J Nucl Med; 1995 Mar; 22(3):207-11. PubMed ID: 7540551
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The value of a baseline bone scan in patients with newly diagnosed prostate cancer.
    Lin K; Szabo Z; Chin BB; Civelek AC
    Clin Nucl Med; 1999 Aug; 24(8):579-82. PubMed ID: 10439178
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Can prostate-specific antigen levels predict bone scan evidence of metastases in newly diagnosed prostate cancer?
    Vijayakumar V; Vijayakumar S; Quadri SF; Blend MJ
    Am J Clin Oncol; 1994 Oct; 17(5):432-6. PubMed ID: 7522394
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prostate specific antigen and bone scan correlation in the staging and monitoring of patients with prostatic cancer.
    Miller PD; Eardley I; Kirby RS
    Br J Urol; 1992 Sep; 70(3):295-8. PubMed ID: 1384920
    [TBL] [Abstract][Full Text] [Related]  

  • 17. When is a bone scan study appropriate in asymptomatic men diagnosed with prostate cancer?
    Pal RP; Thiruudaian T; Khan MA
    Asian J Androl; 2008 Nov; 10(6):890-5. PubMed ID: 18958353
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Serum prostate-specific antigen as a predictor of staging abdominal/pelvic computed tomography in newly diagnosed prostate cancer.
    Huncharek M; Muscat J
    Abdom Imaging; 1996; 21(4):364-7. PubMed ID: 8661585
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Predictive value of prostate-specific antigen and Gleason sum for results of radionuclide bone scintigraphy in patients with prostate cancer].
    Wang TY; Chen XP; Li XS; Jia Yx; Cheng J; Zhang JH; Cai L; Zhang Z; Gong K; He ZS; Zhou LQ
    Beijing Da Xue Xue Bao Yi Xue Ban; 2012 Aug; 44(4):528-34. PubMed ID: 22898839
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ability of serum prostate-specific antigen levels to predict normal bone scans in patients with newly diagnosed prostate cancer.
    Gleave ME; Coupland D; Drachenberg D; Cohen L; Kwong S; Goldenberg SL; Sullivan LD
    Urology; 1996 May; 47(5):708-12. PubMed ID: 8650870
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.